Oryzon Genomics SA
MAD:ORY

Watchlist Manager

Oryzon Genomics SA

MAD:ORY

Watchlist

Dividends

Discount Rate

Price: 1.51 EUR -1.56%

Market Cap: 96.3m EUR

Have any thoughts about
Oryzon Genomics SA?

Write Note

Write Note Create Alert Ask AI

Add Note Why Create Notes?

Capture your thoughts

Note Buy Sell Hold Pass

US	Johnson & Johnson NYSE:JNJ	Pharmaceuticals
US	Berkshire Hathaway Inc NYSE:BRK.A	Financial Services
US	Bank of America Corp NYSE:BAC	Banking
US	Mastercard Inc NYSE:MA	Technology
US	UnitedHealth Group Inc NYSE:UNH	Health Care
US	Exxon Mobil Corp NYSE:XOM	Energy
US	Pfizer Inc NYSE:PFE	Pharmaceuticals
US	Palantir Technologies Inc NYSE:PLTR	Technology
US	Nike Inc NYSE:NKE	Textiles, Apparel & Luxury Goods
US	Visa Inc NYSE:V	Technology
CN	Alibaba Group Holding Ltd NYSE:BABA	Retail
US	3M Co NYSE:MMM	Industrial Conglomerates
US	JPMorgan Chase & Co NYSE:JPM	Banking
US	Coca-Cola Co NYSE:KO	Beverages
US	Walmart Inc NYSE:WMT	Retail
US	Verizon Communications Inc NYSE:VZ	Telecommunication

Add Price Alert

Price Target:

Last Price: 1.51 EUR

We'll email you a reminder when the closing price reaches USD.

If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.

Peter Lynch

Track and Analyze Performance

Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.

Continuous Learning and Adaptation

Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.

Boost Decision Confidence

With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.

Why create notes?

Back

Delete Note

Do you really want to delete this note?
This action cannot be undone.

Remove price alert for reaching

Delete

Cancel

ORY Alert

Oryzon Genomics SA

1.51

-0.024 (-1.56%)

52 Week Range	1.508 2.215
Price Target

We'll email you a reminder when the closing price reaches EUR.

Save Alert

Choose the stock you wish to monitor with a price alert.

	Johnson & Johnson NYSE:JNJ	US
	Berkshire Hathaway Inc NYSE:BRK.A	US
	Bank of America Corp NYSE:BAC	US
	Mastercard Inc NYSE:MA	US
	UnitedHealth Group Inc NYSE:UNH	US
	Exxon Mobil Corp NYSE:XOM	US
	Pfizer Inc NYSE:PFE	US
	Palantir Technologies Inc NYSE:PLTR	US
	Nike Inc NYSE:NKE	US
	Visa Inc NYSE:V	US
	Alibaba Group Holding Ltd NYSE:BABA	CN
	3M Co NYSE:MMM	US
	JPMorgan Chase & Co NYSE:JPM	US
	Coca-Cola Co NYSE:KO	US
	Walmart Inc NYSE:WMT	US
	Verizon Communications Inc NYSE:VZ	US

Delete Alert

This alert will be permanently deleted.

Remove note

Delete

Cancel

Ask me anything about

Oryzon Genomics SA

What unique competitive advantages
does Oryzon Genomics SA hold over its rivals?

What risks and challenges
does Oryzon Genomics SA face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Provide an overview of the primary business activities
of Oryzon Genomics SA.

What unique competitive advantages
does Oryzon Genomics SA hold over its rivals?

What risks and challenges
does Oryzon Genomics SA face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Oryzon Genomics SA.

Provide P/S
for Oryzon Genomics SA.

Provide P/E
for Oryzon Genomics SA.

Provide P/OCF
for Oryzon Genomics SA.

Provide P/FCFE
for Oryzon Genomics SA.

Provide P/B
for Oryzon Genomics SA.

Provide EV/S
for Oryzon Genomics SA.

Provide EV/GP
for Oryzon Genomics SA.

Provide EV/EBITDA
for Oryzon Genomics SA.

Provide EV/EBIT
for Oryzon Genomics SA.

Provide EV/OCF
for Oryzon Genomics SA.

Provide EV/FCFF
for Oryzon Genomics SA.

Provide EV/IC
for Oryzon Genomics SA.

Show me price targets
for Oryzon Genomics SA made by professional analysts.

What are the Revenue projections
for Oryzon Genomics SA?

How accurate were the past Revenue estimates
for Oryzon Genomics SA?

What are the Net Income projections
for Oryzon Genomics SA?

How accurate were the past Net Income estimates
for Oryzon Genomics SA?

What are the EPS projections
for Oryzon Genomics SA?

How accurate were the past EPS estimates
for Oryzon Genomics SA?

What are the EBIT projections
for Oryzon Genomics SA?

How accurate were the past EBIT estimates
for Oryzon Genomics SA?

Compare the revenue forecasts
for Oryzon Genomics SA with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Oryzon Genomics SA and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Oryzon Genomics SA against its competitors.

Analyze the profit margins
(gross, operating, and net) of Oryzon Genomics SA compared to its peers.

Compare the P/E ratios
of Oryzon Genomics SA against its peers.

Discuss the investment returns and shareholder value creation
comparing Oryzon Genomics SA with its peers.

Analyze the financial leverage
of Oryzon Genomics SA compared to its main competitors.

Show all profitability ratios
for Oryzon Genomics SA.

Provide ROE
for Oryzon Genomics SA.

Provide ROA
for Oryzon Genomics SA.

Provide ROIC
for Oryzon Genomics SA.

Provide ROCE
for Oryzon Genomics SA.

Provide Gross Margin
for Oryzon Genomics SA.

Provide Operating Margin
for Oryzon Genomics SA.

Provide Net Margin
for Oryzon Genomics SA.

Provide FCF Margin
for Oryzon Genomics SA.

Show all solvency ratios
for Oryzon Genomics SA.

Provide D/E Ratio
for Oryzon Genomics SA.

Provide D/A Ratio
for Oryzon Genomics SA.

Provide Interest Coverage Ratio
for Oryzon Genomics SA.

Provide Altman Z-Score Ratio
for Oryzon Genomics SA.

Provide Quick Ratio
for Oryzon Genomics SA.

Provide Current Ratio
for Oryzon Genomics SA.

Provide Cash Ratio
for Oryzon Genomics SA.

What is the historical Revenue growth
over the last 5 years for Oryzon Genomics SA?

What is the historical Net Income growth
over the last 5 years for Oryzon Genomics SA?

What is the current Free Cash Flow
of Oryzon Genomics SA?

Discuss the annual earnings per share (EPS)
trend over the past five years for Oryzon Genomics SA.

EV/EBITDA
Enterprise Value to EBITDA

-21

Current

-24.4

Median

4.2

Industry

Higher than median

Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA

-21

Enterprise Value

95.6m EUR

EBITDA

-4.6m EUR

All Countries

Forward Multiples

			Market Cap	EV/EBITDA
ES		Oryzon Genomics SA MAD:ORY	95.3m EUR	-21
FR		Pharnext SCA OTC:PNEXF	6T USD	-219 476
US		Abbvie Inc NYSE:ABBV	310.2B USD	15.2
US		Amgen Inc NASDAQ:AMGN	142B USD	16.1
US		Gilead Sciences Inc NASDAQ:GILD	115B USD	10.1
US		Vertex Pharmaceuticals Inc NASDAQ:VRTX	101.6B USD	20.8
US	E	Epizyme Inc F:EPE	94.1B EUR	-514.8
AU		CSL Ltd ASX:CSL	134.4B AUD	19.7
US		Regeneron Pharmaceuticals Inc NASDAQ:REGN	78.5B USD	15.3
US	S	Seagen Inc F:SGT	39.3B EUR	-58.8
NL		argenx SE XBRU:ARGX	36B EUR	-109.5

				EBITDA Growth	EV/EBITDA to Growth
ES		Oryzon Genomics SA MAD:ORY	Average EV/EBITDA: 16.2 Negative Multiple: -21	N/A	N/A
FR		Pharnext SCA OTC:PNEXF	Negative Multiple: -219 476	N/A	N/A
US		Abbvie Inc NYSE:ABBV	15.2	29%	0.5
US		Amgen Inc NASDAQ:AMGN	16.1	62%	0.3
US		Gilead Sciences Inc NASDAQ:GILD	10.1	16%	0.6
US		Vertex Pharmaceuticals Inc NASDAQ:VRTX	20.8	43%	0.5
US	E	Epizyme Inc F:EPE	Negative Multiple: -514.8	N/A	N/A
AU		CSL Ltd ASX:CSL	19.7	42%	0.5
US		Regeneron Pharmaceuticals Inc NASDAQ:REGN	15.3	35%	0.4
US	S	Seagen Inc F:SGT	Negative Multiple: -58.8	N/A	N/A
NL		argenx SE XBRU:ARGX	Negative Multiple: -109.5	N/A	N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward

EV/EBITDA

-22.4

2-Years Forward

EV/EBITDA

77.6

3-Years Forward

EV/EBITDA

-19.9

	Franklin Covey Co NYSE:FC	36.75 USD 0.93%
	Mohawk Industries Inc NYSE:MHK	118.71 USD -0.38%
	Ardmore Shipping Corp NYSE:ASC	11.5 USD 1.68%
	ASGN Inc NYSE:ASGN	83.9 USD 0.04%
	Skyworks Solutions Inc NASDAQ:SWKS	89.99 USD 1.4%
	Weatherford International PLC NASDAQ:WFRD	67.725 USD 0.93%

	Johnson & Johnson NYSE:JNJ	143.68 USD -0.55%
	Bank of America Corp NYSE:BAC	43.795 USD -0.85%
	Mastercard Inc NYSE:MA	523.31 USD -0.9%
	Salesforce Inc NYSE:CRM	338.137 USD -1.6%
	Abbvie Inc NYSE:ABBV	175.19 USD -0.22%
	Home Depot Inc NYSE:HD	388.75 USD -0.98%

	Arista Networks Inc NYSE:ANET	112.33 USD -0.43%
	Visa Inc NYSE:V	314.32 USD -1.07%
	Texas Pacific Land Corp NYSE:TPL	1 126.655 USD -0.57%
	KLA Corp NASDAQ:KLAC	638.54 USD 1.46%
	Manhattan Associates Inc NASDAQ:MANH	277.71 USD -0.91%
	Pinduoduo Inc NASDAQ:PDD	99.61 USD 0.1%

	Salesforce Inc NYSE:CRM	338.137 USD -1.6%
	Accenture PLC NYSE:ACN	358.57 USD -2.13%
	ServiceNow Inc NYSE:NOW	1 078.9501 USD -1.13%
	EOG Resources Inc NYSE:EOG	118.61 USD -0.36%
	Copart Inc NASDAQ:CPRT	57.85 USD -0.64%
	Applied Materials Inc NASDAQ:AMAT	166.28 USD 1.64%

Oryzon Genomics SA
MAD:ORY

EV/EBITDA
Enterprise Value to EBITDA

EV/EBITDA Forward Multiples

See Also

Company

Help

Tools

Stocks

Oryzon Genomics SA MAD:ORY

EV/EBITDA Enterprise Value to EBITDA

EV/EBITDA Forward Multiples

See Also

Company

Help

Tools

Stocks

Oryzon Genomics SA
MAD:ORY

EV/EBITDA
Enterprise Value to EBITDA